No Increased Risk of Thromboembolic Events During 6‐Month Treatment With Baricitinib in Patients With Alopecia Areata

Documenti analoghi

• Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies
  di: Giacomo Caldarola, et al.
  Pubblicazione: (2024)
• Long‐Term Real‐World Safety Profile of Secukinumab Assessed Through a 9‐Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study
  di: Elena Ippoliti, et al.
  Pubblicazione: (2025)
• Artificial Intelligence and Trichoscopy: Can AI Distinguish Between Alopecia Areata and Lichen Planopilaris?
  di: Daniele Omar Traini, et al.
  Pubblicazione: (2026)
• Therapeutic Response of Alopecia Areata‐Associated Nail Changes to Baricitinib
  di: Ashley Wittmer, et al.
  Pubblicazione: (2024)
• Stigmatizing attitudes towards facial psoriasis, atopic dermatitis, vitiligo and alopecia areata
  di: Eleonora De Luca, et al.
  Pubblicazione: (2025)